ISSN PRINT 2319 1775 Online 2320 7876

Research paper © 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, S Iss 4 ,2022

Clinical Pharmacology for New-Borns

Dr. Jyotsna Sharma[1]*, Dr. Shaktibala Dutta[2], Dr. Vaishali Lote[3]

[1] Professor, Department of Pharmacology, Santosh Medical College and Hospital, Santosh Deemed to be University, Ghaziabad, India

[2] Professor, Department of Pharmacology, Santosh Medical College and Hospital, Santosh Deemed to be University, Ghaziabad, India

[3] Assistant Professor, Department of Pharmacology, Santosh Medical College and Hospital, Santosh Deemed to be University, Ghaziabad, India

ABSTRACT:

Neonatal medication administration should be based on an integrated understanding of the developing physiological characteristics of the newborn receiving the medicine as well as the pharmacokinetics (PK) and pharmacodynamics (PD) of a specific drug. Because of this, neonatal clinical pharmacology is as dynamic and varied as the neonates we admit to our units, and the factors that account for the variability are at least as important as median estimates. Given the risks of extrapolating maturational drug clearance solely based on "adult" metabolism, the special circumstances of neonatal clinical pharmacology will be underlined (propofol, paracetamol). Furthermore, not all maturational processes progress at the same rate. The distinctions between hepatic and renal maturation will be used to highlight this (tramadol, morphine, midazolam). Finally, pharmacogenetics should be customised for newborns rather than simply reflecting adult notions. Due to this variability, neonatal clinical pharmacology clinical research is desperately needed, and PK/PD modelling can help with this. Furthermore, pharmacovigilance is required to identify specific adverse effects regardless of the evidence that is currently available to guide medication. Therefore, paediatric anesthesiologists ought to think about making a contribution to better pharmacotherapy by working together on clinical trial design and reporting on side effects of certain medications.

Keywords*:* Pharmacokinetics; Pharmacodynamics; Newborn; Infant; Anesthesia; Ontogeny

INTRODUCTION:

When a medicine is delivered, the goal is to achieve a proportionate therapeutic effect (such as analgesia, sedation, or muscle relaxation), ideally without experiencing any disproportionally severe side effects (such as extended drowsiness, hypotension, or poisoning). Clinical pharmacology uses drug-, population-, and patient-specific pharmacokinetics (PK) and pharmacodynamics to forecast these (unfavourable) consequences (PD). In terms of "what the body does to the drug," PK describes the relationship between a drug's concentration at a certain place (such as plasma or cerebrospinal fluid) and time. The link between a drug concentration at a certain site and (unfavourable) consequences (i.e., "what the drug causes to the body") is described by PD. Of

ISSN PRINT 2319 1775 Online 2320 7876

Research paper **© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, S Iss 4 ,2022**

course, newborns also fall under the broad principles of clinical pharmacology, but given their unique characteristics, a population-focused strategy is called for (1–5). The neonatal cardiovascular system, lung, and brain are just a few of the issues discussed in this special issue on neonates that highlight these unique traits, which mostly relate to developmental physiology. The neonatal gasping syndrome (benzyl alcohol toxicity, co-administered as an excipient in the setting of impaired alcohol clearance capacity), the grey baby syndrome (chloramphenicol toxicity related to impaired glucuronidation), or hexachlorophene bathing (increased transcutaneous absorption and limited clearance capacity, aimed to reduce impetigo) encephalopathy all illustrate the obvious clinical need to learn more about neonatal pharm (1–10).

A set of concurrent physiological events that cause both growth and maturity throughout a child's life make up growth and development, which are frequently split into subpopulations (newborn, infancy, childhood, and adolescence). Organ size and function, body composition, and eventually cellular and metabolic activity vary over the course of this juvenile life span. Population-specific pharmacokinetics will be impacted by this (6–10). Additionally, depending on the dose or level of exposure, some tissues may be more or less responsive to the pharmacologic effects early in life. Population-specific pharmacodynamics will be impacted by this (6–10). Similar to dexamethasone (impaired cerebral growth, cerebral palsy) (12) or exposure to nephrotoxic substances during nephrogenesis in preterm neonates (reduced number of glomeruli, up to 34–36 weeks postmenstrual age), the issue of apoptosis following exposure to analgosedatives and anaesthetics during infancy reflects such population-specific vulnerability (11, 13).

The term "absorption" refers to physicochemical properties and patient factors that affect how a certain molecule is transported from its exposure site (such as the enteral, pulmonary, or cutaneous) to the bloodstream or another effect compartment. The term "distribution" refers to the movement of a specific drug across the body's tissues, organs, and fluid spaces. This movement is frequently measured by the distribution volume [Vd = total amount of a given drug/concentration]. While this volume of distribution may not exactly correspond to a physiological volume or space, maturational physiological changes such changes in body composition, regional blood flow, organ size, barriers, or plasma protein concentrations frequently have an impact on it. Together, metabolism and excretion (also known as elimination clearance) indicate the clearance capacity, which is the amount of blood or plasma that a drug can totally remove in a given amount of time provides examples of how population-specific variables can affect the pharmacokinetics of medications also given during surgery (1, 9, 14–24).

Some paracetamol PD features, however, might be unique to the newborn population. There have been reports linking paracetamol exposure during infancy or even during pregnancy to an increased chance of developing atopy-related disorders, albeit these reports do not necessarily prove causation. Even more intriguing, studies linking paracetamol exposure to the closure of the patent ductus arteriosus in a small number of extremely preterm infants

ISSN PRINT 2319 1775 Online 2320 7876

Research paper **© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, S Iss 4 ,2022**

have been published. However, because a connection between the physiology of ductal closure and the pharmacology of paracetamol is unclear, causality cannot yet be assumed. This is because paracetamol is thought to be a subpar anti-inflammatory and antithrombotic drug with minimal effects at peripheral locations.

Recent studies have examined how the development of absorption, distribution, metabolism, and elimination affects PK in newborns. Due to the risks of extrapolating maturational drug clearance based solely on "adult" metabolism, the special context of neonatal clinical pharmacology will be underlined (propofol, paracetamol). Second, not all maturational processes move forward at the same rate. On the basis of the distinctions between hepatic and renal maturation, this will be demonstrated (tramadol, morphine, midazolam). Last but not least, pharmacogenetics should be customised for neonates rather than simply reflecting adult conceptions.

DISCUSSION

Neonatal drug metabolism is not just a 'miniaturized' adult pattern

Drug biotransformation and elimination depend heavily on drug metabolising enzymes. Consequently, neonatal drug clearance will be impacted by drug metabolising isoenzyme-specific ontogeny. The expression of drug metabolising enzymes undergoes significant changes during development, which have an impact on medication action and the likelihood of adverse events in the neonate (7,8,10). Based on developmental trajectories, current understanding shows that each drug metabolising isoenzyme can be divided into one of three groups. In foetal life, a first group of enzymes, including CYP3A7 and SULT1A3/1A4, are expressed at their maximum levels. Over the first two years of life, they will become less active and eventually vanish. The second category consists of enzymes (such as CYP3A5, CYP2C19, and SULT1A1) that show only a slight increase after birth before becoming more active later in childhood. The third group, which includes the genes for CYP2D6, CYP3A4, CYP2C9, and CYP1A2, exhibits minor ontogeny in the second or third trimester of pregnancy and then experiences an additional important rise in phenotypic activity throughout infancy (7,8,10).

Renal and hepatic maturation: the need for an integrated interpretation

The kidneys and hepatobiliary system are the major organs for the elimination of medicines and metabolites. While metabolic clearance primarily occurs through the liver, primary elimination clearance primarily occurs through the kidneys. Diuresis (free water clearance only), glomerular filtration rate (GFR), and renal tubular activity are indicators of the renal elimination capacity (reabsorption and secretion).

Early infancy is markedly variable due to both maturational factors (such as age and birthweight) and disease-related factors (such as peripartal asphyxia, renal congenital abnormalities, comedication, or growth limitation). The phenotypic diversity in hepatic elimination is connected to constitutional, disease-associated, and hereditary variables,

ISSN PRINT 2319 1775 Online 2320 7876

Research paper **© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, S Iss 4 ,2022**

similar to renal elimination. During infancy, age-dependent phenotypic enzymatic activity is the primary motivator.

The degree of drug biotransformation and elimination are clearly influenced by drug metabolising enzymes, and the development of hepatic drug metabolising enzymes can greatly affect drug clearance during infancy (8–10). However, there are significant differences in the maturation patterns of the various renal or hepatic elimination mechanisms. This suggests that in order to predict compound-specific, phenotypic in vivo observations in neonates, it is crucial to integrate all ontogeny-related knowledge of the various elimination routes. After all, there is no such thing as an isolated neonatal kidney or liver—only newborns who require improved predictability.

Pharmacogenetics should be tailored to neonates, not just mirror adult observations

Pharmacogenetics is based on the idea that a certain impact or risk is not distributed randomly among a (sub)population. Evidently, this holds potential for personalised medication therapy and enhanced predictability in newborns and early infants. On the influence of pharmacogenetics on in vivo phenotypic CYP2D6 (e.g., tramadol, codeine), CYP2C19 (e.g., pantoprazole) (23) or N-acetyl transferase (NAT)2 (44) (e.g., isoniazid) activity in early life, there are published observations (24). To some extent, this still approaches the child as "a small adult" (when does genotype-phenotype concordance appear?). However, such isoenzyme-specific observations have been investigated based on genotype-phenotype concordances as stated in adults. The tramadol and O-demethyl tramadol profiles in a full-term neonate (3.2 kg, 1.5 mgkg1 intravenous bolus tramadol) are affected by the CYP2D6 activity score (0.5 vs 3).

How to handle ever more compounds in search of guidance

The current newborn special issue reflects the advancement in understanding of several (patho)physiological characteristics in this particular population, which paediatric anesthesiologists frequently refer to due to surgical interventions or analgosedation to facilitate procedural interventions. This expansion of understanding includes drug therapy for newborns. Off-label use is nevertheless still frequent, and neonatal evidence-based medication is scarce. Designing and participating in well planned trials on the PK/PD of the drugs often delivered by paediatric anesthesiologists, using acceptable formulations and assessment procedures, is the best way to close this gap.

A notable example of its viability is the recently released research on the opioid sparing effects of intravenous paracetamol in noncardiac newborns (22). The key outcome variables of opioid decrease in neonates may be different from those typically thought of (such as drowsiness, bladder retention, and constipation), but may relate to neurodevelopmental outcome, according to newly available information on neuroapoptosis (11). The good news is that research is still still being done.

CONCLUSION

ISSN PRINT 2319 1775 Online 2320 7876

Research paper © 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, S Iss 4 ,2022

Despite the fact that trial data is available to direct pharmacotherapy in neonates, doctors must be aware that the majority of trials are primarily relevant to assess efficacy. Studies are not the best way to get information on (rare) negative drug effects because pharmacovigilance and surveillance after widespread usage is required. Researchers and physicians should keep an eye out for such effects and report particular observations, in addition to the regulatory agencies. We use recent studies on propofol infusion syndrome in young infants, delirium, and opioid-induced hyperalgesia to demonstrate this.

REFERENCE:

1. Anderson BJ, Allegaert K. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesthesiol 2010; 24: 419–431.
2. Smits A, Kulo A, de Hoon JN et al. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des 2012; 18: 3119–3146.
3. Anderson BJ. Pharmacology in the very young: anaesthetic implications. Eur J Anaesthesiol 2012; 29: 261–270.
4. Sumpter A, Anderson BJ. Pediatric pharmacology in the first year of life. Curr Opin Anaesthesiol 2009; 22: 469–475.
5. Allegaert K, Verbesselt R, Naulaers G et al. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008; 63: 16–24.
6. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25–36.
7. van den Anker JN. Developmental pharmacology. Dev Disabil Res Rev 2010; 16: 233–238.
8. Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011; 7: 935–948.
9. Cote CJ, Ward RM, Lugo RA et al. Pharmacokinetics and pharmacology of drugs used in children (section II, chapter 6). In: Cote CJ, Lerman J, Todres ID, eds. A Practice of Anesthesia for Infants and Children, 4th edn. Philadelphia, PA: Saunders Elsevier, 2009: 89–146.
10. Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharmdoi doi: 10.1016/j.ijpharm.2012.05. 079.
11. Davidson AJ. Anesthesia and neurotoxicity to the developing brain: the clinical relevance. Pediatr Anesth 2011; 21: 716–721.

ISSN PRINT 2319 1775 Online 2320 7876

Research paper **© 2012 IJFANS. All Rights Reserved, UGC CARE Listed (Group -I) Journal Volume 11, S Iss 4 ,2022**

12. Shinwell ES, Eventov-Friedman S. Impact of perinatal corticosteroids on neuromotor development and outcome: review of the literature and new meta-analysis. Semin Fetal Neonatal Med 2009; 14: 164–170.

13. Zaffanello M, Bassareo PP, Cataldi L et al. Long-term effects of neonatal drugs on the kidney. J Matern Fetal Neonatal Med 2010; 23(Suppl 3): 87–89.

14. Yilmaz D, Tezic HT, Zorlu P et al. Single dose povidone-iodine on thyroid functions and urinary iodine excretion. Indian J Pediatr 2003; 70: 675–677.

15. Smits A, Kulo A, Verbesselt R et al. Cefazolin plasma protein binding and its covariates in neonates. Eur J Clin Microbiol Infect Dis 2012; 31: 3359–3365.

16. Calder A, Bell GT, Andersson M et al. Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. Pediatr Anesth 2012; 22: 430–437.

17. Allegaert K, de Hoon J, Verbesselt R et al. Maturational pharmacokinetics of single intravenous bolus of propofol. Pediatr Anesth 2007; 17: 1028–1034.

18. Smits A, Verbesselt R, Kulo A et al. Urinary metabolites after intravenous propofol bolus in neonates. Eur J Drug Metab Pharmacokinet doi: 10.1007/s13318-012-0109-6.

19. Welzing L, Kribs A, Eifinger F et al. Propofol as an induction agent for endotracheal intubation can cause significant arterial hypotension in preterm neonates. Pediatr Anesth 2010; 20: 605–611.

20. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011; 96: 575–580.

21. Anderson BJ, Allegaert K. Intravenous neonatal paracetamol dosing: the magic of 10 days. Pediatr Anesth 2009; 19: 289–295.

22. Anderson BJ, Larsson P. A maturation model for midazolam clearance. Pediatr Anesth 2011; 21: 302–308.

23. Larson A, Stidman T, Banerji S et al. Seizures and methemoglobinemia in an infant after excessive EMLA application. Pediatr Emerg Care 2013; 29: 377–379.

24. Sistonen J, Madadi P, Ross CJ et al. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 2012; 91: 692–699.